Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 4/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635916 | 0.90 | KDM4E (0.41) | KDM4ELMNAALDH1A1HPGDHTT | |
| SCHEMBL4635615 | 0.81 | GPBAR1 (0.44) | KDM4ELMNAALDH1A1HTTHSD17B10 | |
| SCHEMBL4635329 | 0.80 | KDM4E (0.43) | KDM4ELMNAALDH1A1HPGDHTT | |
| SCHEMBL4634235 | 0.78 | CCR1 (0.42) | ALDH1A1HPGDHTTFKBP1A | |
| SCHEMBL5671951 | 0.78 | PKM (0.45) | KDM4ELMNAALDH1A1HPGDHTT | |
| SCHEMBL4635736 | 0.77 | ALDH1A1 (0.45) | KDM4ELMNAALDH1A1HPGDHTT | |
| SCHEMBL4634118 | 0.75 | NPC1 (0.43) | KDM4EALDH1A1HPGDFKBP1A | |
| SCHEMBL4634724 | 0.75 | TDP1 (0.42) | KDM4ELMNAALDH1A1HTT | |
| SCHEMBL4634714 | 0.75 | POLB (0.52) | KDM4ELMNAALDH1A1HPGDHTT | |
| SCHEMBL5673252 | 0.74 | PTGDR2 (0.43) | KDM4ELMNAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | claimed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | claimed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | claimed |
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | CCR1, CCR2, CCR3 | KDM4E 4378/4885MCHR1 750/4885LMNA 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.